18 Nov 2025
TAVI in 2025: transforming care with the new valvular heart disease guidelines
Sponsored by Edwards Lifesciences
Anchorperson:
C. Cook
Spokesperson:
M. Leon
Summary
This session explores how the 2025 valvular heart disease guidelines are transforming the landscape of TAVI care and clinical decision-making. It highlights the paradigm shift in managing severe aortic stenosis and provides a global perspective on the challenges and strategies for managing an expanding TAVI patient population through multidisciplinary approaches and streamlined evaluation.
Learning Objectives
- To understand how the 2025 valvular heart disease guidelines are reshaping TAVI care and clinical decision-making
- To engage with the paradigm shift in the contemporary management of severe aortic stenosis
- To gain a global perspective on addressing the challenges of an expanding TAVI population
/slide001.jpg)
/slide002.jpg)
/slide003.jpg)
/slide004.jpg)
/slide006.jpg)
/slide007.jpg)
/slide001.jpg)
/slide002.jpg)
/slide003.jpg)
/slide005.jpg)
/slide006.jpg)
/slide007.jpg)
/slide008.jpg)
/slide010.jpg)
/slide011.jpg)
/slide012.jpg)
/slide014.jpg)
/slide015.jpg)
/slide016.jpg)
/slide017.jpg)
/slide018.jpg)
/slide019.jpg)
/slide020.jpg)
/slide000.jpg)
/slide001.jpg)
/slide002.jpg)
/slide003.jpg)
/slide004.jpg)
/slide005.jpg)
/slide006.jpg)
/slide007.jpg)
/slide008.jpg)
/slide009.jpg)
/slide010.jpg)
/slide011.jpg)
/slide012.jpg)
/slide013.jpg)
/slide014.jpg)
/slide015.jpg)
/slide016.jpg)